The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 02, 2025

Filed:

Apr. 22, 2020
Applicants:

Bayer Aktiengesellschaft, Leverkusen, DE;

The Broad Institute, Inc., Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Franziska Siegel, Cambridge, MA (US);

Daniel Korr, Berlin, DE;

Jens Schröder, Berlin, DE;

Stephan Siegel, Berlin, DE;

Heidi Greulich, Cambridge, MA (US);

Bethany Kaplan, Cambridge, MA (US);

Matthew Meyerson, Boston, MA (US);

Assignees:

Bayer Aktiengesellschaft, Leverkusen, DE;

The Broad Institute, Inc., Cambridge, MA (US);

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/5377 (2013.01); A61K 38/179 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 471/04 (2013.01);
Abstract

Compounds of formula (I) for use in the treatment or prophylaxis of a disease, which is a hyperproliferative disease and/or a disorder responsive to induction of cell death, selected from a haematological tumour, a solid tumour and/or metastases thereof, said tumour harbouring a mutant EGFR with exon 19 or 21 mutations, and their use as pharmaceuticals.


Find Patent Forward Citations

Loading…